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Summary
Background Targeted preventive therapy for individuals at highest risk of incident tuberculosis might impact the 
epidemic by interrupting transmission. We tested performance of a transcriptomic signature of tuberculosis (RISK11) 
and efficacy of signature-guided preventive therapy in parallel, using a hybrid three-group study design.
Methods Adult volunteers aged 18–59 years were recruited at five geographically distinct communities in South 
Africa. Whole blood was sampled for RISK11 by quantitative RT-PCR assay from eligible volunteers without HIV, 
recent previous tuberculosis (ie, <3 years before screening), or comorbidities at screening. RISK11-positive participants 
were block randomised (1:2; block size 15) to once-weekly, directly-observed, open-label isoniazid and rifapentine for 
12 weeks (ie, RISK11 positive and 3HP positive), or no treatment (ie, RISK11 positive and 3HP negative). A subset of 
eligible RISK11-negative volunteers were randomly assigned to no treatment (ie, RISK11 negative and 3HP negative). 
Diagnostic discrimination of prevalent tuberculosis was tested in all participants at baseline. Thereafter, prognostic 
discrimination of incident tuberculosis was tested in the untreated RISK11-positive versus RISK11-negative groups, 
and treatment efficacy in the 3HP-treated versus untreated RISK11-positive groups, during active surveillance through 
15 months. The primary endpoint was microbiologically confirmed pulmonary tuberculosis. The primary outcome 
measures were risk ratio [RR] for tuberculosis of RISK11-positive to RISK11-negative participants, and treatment 
efficacy. This trial is registered with ClinicalTrials.gov, NCT02735590.
Findings 20 207 volunteers were screened, and 2923 participants were enrolled, including RISK11-positive 
participants randomly assigned to 3HP (n=375) or no 3HP (n=764), and 1784 RISK11-negative participants. 
Cumulative probability of prevalent or incident tuberculosis disease was 0·066 (95% CI 0·049 to 0·084) in RISK11-
positive (3HP negative) participants and 0·018 (0·011 to 0·025) in RISK11-negative participants (RR 3·69, 95% CI 
2·25–6·05) over 15 months. Tuberculosis prevalence was 47 (4·1%) of 1139 versus 14 (0·78%) of 1984 in RISK11-
positive compared with RISK11-negative participants, respectively (diagnostic RR 5·13, 95% CI 2·93 to 9·43). 
Tuberculosis incidence over 15 months was 2·09 (95% CI 0·97 to 3·19) vs 0·80 (0·30 to 1·30) per 100 person years 
in RISK11-positive (3HP-negative) participants compared with RISK11-negative participants (cumulative incidence 
ratio 2·6, 95% CI 1·2 to 5·9). Serious adverse events related to 3HP included one hospitalisation for seizures 
(unintentional isoniazid overdose) and one death of unknown cause (possibly temporally related). Tuberculosis 
incidence over 15 months was 1·94 (95% CI 0·35 to 3·50) versus 2·09 (95% CI 0·97 to 3·19) per 100 person-years 
in 3HP-treated RISK11-positive participants compared with untreated RISK11-positive participants (efficacy 7·0%, 
95% CI –145 to 65).
Interpretation The RISK11 signature discriminated between individuals with prevalent tuberculosis, or progression to 
incident tuberculosis, and individuals who remained healthy, but provision of 3HP to signature-positive individuals 
after exclusion of baseline disease did not reduce progression to tuberculosis over 15 months.
Funding Bill and Melinda Gates Foundation, South African Medical Research Council.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Large-scale prevention of progression from Myco­
bacterium tuberculosis infection to tuberculosis disease is 
key to achieving WHO End TB Strategy targets, yet 
tuberculin skin tests (TST) and interferon (IFN) γ release 
assays have poor specificity for incident tuberculosis.1 A 
biomarker-targeted prevention strategy using a highly 
specific correlate of risk (COR) for incident tuberculosis, 
in tandem with effective short-course tuberculosis pre-
ventive therapy (TPT),2 might impact the epidemic by 
preventing incident tuberculosis disease before trans-
mission.3 Modelling suggests a three-times reduction in 
burden of TPT if targeted by COR, compared with 
IFNγ release assays and TST.4 Furthermore, because 
active tuberculosis disease should be excluded before 
starting TPT, additional utility of the prognostic COR 
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as a screening (triage) test to identify undiagnosed 
tuberculosis disease would allow earlier curative treat-
ment. WHO and FIND have developed target product 
profiles (TPP) for triage tests for tuberculosis (optimal 
and minimum sensitivity of >95% and >90%, and 
specificity of >80% and >70%, respectively),5 and incipient 
tuberculosis tests (minimum sensitivity and specificity of 
75% and 75%, and optimal sensitivity and specificity of 
90% and 90%, respectively).6
We previously developed a 16-gene transcriptomic 
signature by whole blood RNA sequencing for identi-
fication of individuals at high risk of developing tuber-
culosis (the Zak16 signature).7,8 Measurement of Zak16 
was adapted to quantitative RT-PCR (RT-qPCR), and 
predictive ability for incident tuberculosis was validated 
in an independent longitudinal cohort of household 
contacts of tuberculosis patients.8 We reduced this 
signature to 11 genes (RISK11) with equivalent perfor-
mance,9,10 to allow testing in 96-well PCR format. Zak16 
and RISK11 also did well as non-sputum screening 
tests for prevalent, active tuberculosis in case-control 
studies, measured by RNA sequencing, microarray,7,8 or 
microfluidic RT-qPCR.9,10 In a 2020 systematic review and 
patient-level pooled meta-analysis of 17 tran scriptomic 
signatures for prognosis of incident tuberculosis, Zak16 
was among eight signatures that achieved a positive 
predictive value above the WHO TPP benchmark for 
incipient tuberculosis tests.11 Since case-control studies 
might overestimate performance characteristics, testing 
in unselected populations is needed.
We report on a randomised controlled trial (CORTIS; 
NCT02735590), which prospectively measured diagnostic 
and prognostic performance of RISK11 for triage of 
prevalent and prediction of incident tuberculosis in South 
African adults; and, in parallel, estimated efficacy of 




This randomised controlled trial used a hybrid treat ment 
selection, three-group study design to evaluate efficacy 
of the intervention and, in parallel, performance of the 
biomarker used to allocate that intervention (figure 1).2 The 
Research in context
Evidence before this study
Host blood RNA signatures have potential as tuberculosis triage 
or diagnostic tests, and as predictive tests to target tuberculosis 
preventive therapy. We searched MEDLINE, Scopus, Web of 
Science, and EBSCO libraries for publications between 
Jan 1, 2005, and May 31, 2020, using the search terms 
“Tuberculosis” OR “TB” OR “Mycobacterium tuberculosis” OR 
“MTB” AND “diagnosis” OR “diagnostic” OR “detect” OR 
“predic”OR “prognosis” OR “prognostic” OR “screen” AND 
“Blood Biomarker” OR “blood biomarkers” OR “bio-signature” 
OR “gene expression” OR “genetic transcription” OR “host 
blood” OR “immune marker” OR “immunologic marker” OR 
“Ribonucleic Acid” OR “RNA” OR “signature” OR “surrogate 
endpoint” OR “surrogate marker” OR “transcriptome” OR 
“transcriptomic” AND “Area under curve” OR “AUC” OR 
“receiver operating characteristic” OR “ROC” OR “Accuracy” OR 
“Performance” OR “sensitivity” OR “specificity”. Studies 
comparing blood RNA signatures in individuals with 
tuberculosis versus Mycobacterium tuberculosis-uninfected 
controls, individuals with other respiratory diseases, or with 
M tuberculosis infection and using a microbiological reference 
standard of either sputum M tuberculosis culture, 
Xpert MTB/RIF, or smear microscopy for tuberculosis diagnosis, 
were included.
28 studies reported evaluation of 32 host blood RNA signatures 
for diagnosis or prediction of progression to tuberculosis 
disease in 83 cohorts. Only two studies prospectively tested 
performance of an RNA signature in all evaluable participants; 
the remainder used a case-control design. Multiple studies 
have tested tuberculosis preventive therapy in people with 
M tuberculosis latent tuberculosis infection. No studies have 
tested efficacy of tuberculosis preventive therapy to avert 
disease in RNA signature-positive people.
Added value of this study
This large randomised, controlled trial in five South African 
communities prospectively tested diagnostic and prognostic 
performance of an RNA signature (RISK11) in all evaluable 
participants, and estimated efficacy of tuberculosis preventive 
therapy to avert disease in RNA signature-positive people. 
More than 1% of HIV-uninfected community volunteers 
had previously undiagnosed, microbiologically confirmed 
tuberculosis at screening, more than 80% of which was 
asymptomatic. RISK11 showed moderate performance for 
tuberculosis triage, but good performance for diagnosis of 
symptomatic tuberculosis, and for short-term prediction of 
incident tuberculosis. 3 months of once-weekly, high-dose 
isoniazid and rifapentine (3HP) did not reduce incident disease 
in RISK11-positive individuals over 15 months of follow-up.
Implications of all the available evidence
Host blood biomarker development must consider that 
subclinical tuberculosis might be characterised by more 
heterogenous, or less pronounced blood inflammatory 
responses than symptomatic tuberculosis, or both, which will 
affect RNA signature performance. RISK11 might be better 
suited to screening of symptomatic individuals with possible 
tuberculosis than for mass community-based screening. 
RISK11 can identify those at highest risk for short-term 
progression to disease, but a more potent regimen than 3HP 
might be needed to prevent tuberculosis in RISK11-positive 
individuals.
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coprimary aims were to test, over 15 months, whether 
RISK11 status differentiates between people with and 
without cumulative prevalent or incident tuberculosis; and 
whether preventive therapy (weekly high-dose isoniazid 
and rifapentine for 12 weeks [3HP]) reduces tuberculosis 
incidence among RISK11-positive people compared with 
active survei llance only. RISK11 performance to detect 
prevalent tuberculosis was evaluated in all groups 
at baseline. RISK11 performance to predict incident 
tuberculosis was evaluated in the untreated RISK11-
positive and RISK11-negative groups, and treatment 
efficacy was estimated from the 3HP treated and untreated 
RISK11-positive groups, after omitting participants with 
baseline tuberculosis. Efficiency of the hybrid study design 
was maximised by using the RISK11-positive and 3HP-
negative group to evaluate both biomarker performance 
and treatment efficacy.
Routine implementation of TPT requires that patients 
are screened to exclude prevalent tuberculosis before TPT 
is provided to prevent incident disease. Therefore, 
because risk for prevalent and incident tuberculosis 
by RISK11 status must be understood before efficacy 
of preventive therapy against incident tuberculosis 
in RISK11-positive people can be interpreted, these 
secondary analyses are presented before the primary 
analysis of treatment efficacy.
The trial protocol (appendix p 21) was approved 
by the South African Health Products Regulatory 
Agency (20160305) by the Institutional Human Ethics 
Committees of participating sites; and was registered 
on ClinicalTrials.gov (NCT02735590). All participants 
provided written informed consent in their language of 
choice.
Participants
Adult volunteers living in tuberculosis-endemic commu-
nities in South Africa were recruited at five sites 
(South African Tuberculosis Vaccine Initiative, Worcester; 
Immunology Research Group, Stellenbosch University, 
Ravensmead; Aurum Institute, Klerksdorp and Rusten-
berg; and Centre for the AIDS Programme of Research in 
South Africa, Durban). Community-based recruitment 
was by word-of-mouth, house-to-house visits, and liaison 
with non-governmental organisations. Recruitment did 
not target groups at high risk of tuberculosis, such as 
household contacts. Eligible participants were aged 
between 18 years and 59 years, HIV-negative, without a 
history of tuberculosis disease in the last 3 years or 
preselected comorbidities (appendix p 8).
Screening
Venous blood was collected in PAXgene RNA tubes from all 
potentially eligible people at screening, frozen at –20°C, and 
shipped weekly to the South African Tuberculosis Vaccine 
Initiative Immunology Laboratory for RISK11 testing by 
qRT-PCR assay. Participants with a RISK11 score of at least 
60% were classified a priori as RISK11 positive and less than 
60% as RISK11 negative. This 60% threshold was the 
optimal point at which sensitivity and specificity for 
prognosis of incident tuberculosis were balanced in case-
control studies.2 Samples with failed reference primer-probe 
reactions, with marked deviation in internal positive control 
sample from historical runs, or more than 30% failed 
interferon-stimulated genes primer-probe reactions (see 
quality control criteria and analysis script in Bitbucket 
instance) were classified as inde terminate. Per-participant 
qualitative results (RISK11 positive and RISK11 negative) 
were provided to the Triclinium Clinical Development 
(TCD) Data Centre for participant randomisation (see 
appendix pp 2–3).
Randomisation and masking
Assignment to study group was managed by an unmasked 
randomisation team from the TCD Data Centre, based on 
RISK11 status. RISK11-positive volunteers were randomly 
Figure 1: Study design
The prevalence of RISK11 positivity was not precisely known in the study population; therefore, the number of 
individuals to be screened and the randomisation of RISK11-negative participants to enrolment was monitored and 
adjusted adaptively to ensure concurrent enrolment of the target number of RISK11-positive and RISK11-negative 
participants, per protocol specifications. The study used a three-group design to evaluate efficacy of the intervention 
and, in parallel, performance of the biomarker used to allocate that intervention. Diagnostic performance for 
differentiation of prevalent tuberculosis was tested in all three groups at baseline; prognostic performance for 
differentiation of incident tuberculosis over 15 months was tested in the two untreated groups (untreated RISK11 
positive and untreated RISK11 negative); and treatment efficacy of 3HP over 15 months was tested in the two 
RISK11-positive groups (treated and untreated RISK11 positive). *Participants evaluated for eligibility at screening 
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3HP negative Not enrolled
1434 (9·3%) RISK11 positive 14060 (91·0%) RISK11 negative
See Online for appendix
Articles
4 www.thelancet.com/infection   Published online January 25, 2021   https://doi.org/10.1016/S1473-3099(20)30914-2
assigned (1:2; block size 15) to either open-label 3HP 
(3HP-positive group), or active tuberculosis surveillance 
without 3HP (3HP-negative group), in accordance with a 
rando misation schedule generated using SAS, version 9.4. 
RISK11-negative volunteers were concurrently randomly 
assigned either to active tuberculosis survei llance 
(3HP-negative group) or to non-participation, to enrich 
the study population for RISK11-positive participants.
Study group allocation was revealed to site staff after 
enrolment of eligible participants within 28 days of 
screening. The 3HP-negative group was double-blinded to 
RISK11 status, but unblinded to treatment allocation; the 
3HP-positive group was unblinded to both RISK11-positive 
status and treatment allocation (figure 1). RISK11-positive 
participants randomly assigned to active surveillance did 
not receive a placebo, to maintain blinding of participants 
and study team members to RISK11 status.
Procedures
Target enrolment was maximally 3200 participants 
(1500 RISK11 positive and 1700 RISK11 negative). The 
randomisation ratio for RISK11-negative volunteers 
was adapted to ensure concurrent enrolment of the 
recruitment target. Adaptations occurred at intervals, 
informed by 3-monthly operational monitoring reports 
based on enrolment rate, RISK11-positive and RISK11-
negative prevalence, and tuberculosis case accrual 
blinded to RISK11 status (appendix p 7).
Enrolment procedures included phlebotomy for IFNγ 
release assays (QuantiFERON TB Gold-Plus, Qiagen), 
tuberculosis symptom screen (a positive tuberculosis 
symptom screen included one or more symptoms of 
persistent unexplained cough, fever, night sweats, 
weight loss, or any haemoptysis), and collection of two 
spontaneous expectorated sputum samples for Xpert 
MTB/RIF assay (Cepheid) from all sputum-productive 
participants, regardless of symptoms.
All participants attended up to seven study visits, 
including four study site visits at months 3, 6, 12, and 15 
(end of study), and three telephonic contact or field visits 
at months 1, 2, and 9. HIV testing was repeated at 
months 6 and 12.
Participants in the 3HP group received open-label, 
high-dose isoniazid (15 mg/kg; maximum dose 900 mg) 
with pyridoxine supplementation (25 mg) and rifapentine 
based on body weight (>32–50 kg, 750 mg; >50 kg, 
900 mg), given weekly as directly observed oral doses, 
ideally with food, over 12 weeks. Completion of 3HP 
treatment was defined as receipt of 11 doses within 
16 weeks (appendix p 3).
Outcomes
The two primary outcome measures were RISK11-
positive to RISK11-negative risk ratio (RR) for prevalent 
or incident tuberculosis disease, and 3HP treatment 
efficacy through 15 months. Diagnostic performance for 
prevalent tuberculosis was evaluated on the presence of 
tuberculosis at the enrolment visit within the ITT cohort.
Participants in the 3HP group had each dose directly 
observed by study staff, and attended clinic for evaluation 
of solicited adverse events and possible adverse events of 
special interest at weeks 1–11. Solicited adverse events 
included gastrointestinal signs and symptoms suggestive 
of hepatotoxicity, such as nausea, vomiting, and jaundice. 
Possible hypersensitivity reactions, including influenza-
like illness, were reported as adverse events of special 
interest. Safety events meeting the definition for a 
serious adverse event, whether deemed related or 
unrelated to study drug, were reported for both all 
participants through end of study.
Statistical analysis
The intention-to-treat (ITT) cohort included all enrolled 
participants who completed investigation for tuberculosis 
endpoints at baseline. The modified intention-to-treat 
(mITT) cohort included all participants in the ITT 
population who completed at least one post-baseline 
tuberculosis endpoint investigation and omitted 
participants with endpoint-defined tuberculosis disease 
at baseline (prevalent tuberculosis).
The diagnostic RR was estimated as a proportion 
of participants with tuberculosis disease among 
RISK11-positive divided by RISK11-negative participants. 
Prognostic performance for incident tuberculosis 
after enrolment was evaluated among 3HP-negative 
partici pants within the mITT cohort (ie, excluding 
participants with tuberculosis at baseline). Prognostic 
RR was estimated as the cumulative incidence through 
15 months for RISK11-positive divided by RISK11-
negative participants. The primary RR was an estimate of 
the probability of having prevalent tuberculosis or 
developing incident tuberculosis among RISK11-positive 
divided by RISK11-negative participants; this combined 
probability of prevalent and incident tuberculosis was 
computed for each group as the probability of prevalent 
tuberculosis plus the probability of incident tuberculosis 
through 15 months (conditioned on not having prevalent 
tubercu losis). Efficacy of 3HP preventive therapy to 
reduce the rate of incident tuberculosis disease compared 
with the untreated RISK11-positive participants was also 
evaluated in the mITT population. Treatment efficacy 
was estimated as one minus the cumulative incidence of 
RISK11-positive and 3HP-positive participants divided by 
RISK11-positive and 3HP-negative participants through 
15 months. A per-protocol analysis of treatment efficacy 
was done and excluded RISK11-positive and 3HP-positive 
participants that received less than 11 of the 12 weekly 
doses of 3HP.
For statistical efficiency, a random subset of RISK11-
negative participants were enrolled, therefore creating an 
ITT cohort artificially enriched with RISK11-positive 
participants. Therefore, unless stated otherwise, all 
analyses were adjusted so that results reflected the 
screened population. Secondary performance metrics 
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such as sensitivity and specificity were estimated using 
standard formulas with binary endpoints; a percentile 
bootstrap with 20 000 samples was used to estimate 
95% CIs. For descriptive analyses (tables 1, 2), rank-based 
Wilcoxon rank-sum tests were used to compare con tinuous 
variables in RISK11-positive versus RISK11-negative 
Prevalent tuberculosis (ITT cohort) Incident tuberculosis (mITT cohort)*
RISK11(60)† RISK11(26)† IGRA RISK11(60)† RISK11(26)† IGRA
Risk ratio 5·13 (2·93 to 9·43) 7·39 (3·46 to 25·69) 4·43 (1·93 to 14·18) 2·61 (1·15 to 5·94) 2·67 (1·04 to 8·66) 2·83 (0·95 to 99·79)
Biomarker prevalence 9·2% (9·2 to 9·2) 25·8% (24·1 to 27·4) 63·4% (61·3 to 65·4) 9·0% (9·0 to 9·0) 25·3% (23·7 to 26·9) 63·2% (61·1 to 65·3)
AUC‡ 0·77 (0·68 to 0·86) ·· 0·66 (0·58 to 0·73) 0·63 (0·47 to 0·80) ·· 0·67 (0·54 to 0·79)
Sensitivity 34·9% (23·7 to 52·2) 72·1% (54·5 to 90·2) 88·7% (77·1 to 96·4) 25·0% (12·7 to 45·9) 47·5% (25·9 to 75·0) 83·2% (61·9 to 100·0)
Specificity 91·0% (90·9 to 91·1) 74·7% (73·1 to 76·4) 36·9% (34·9 to 39·0) 91·1% (91·0 to 91·2) 74·9% (73·2 to 76·5) 37·0% (34·9 to 39·1)
PPV§ 4·1% (3·0 to 5·4) 3·1% (2·0 to 4·3) 1·5% (1·0 to 2·2) 1·9% (0·9 to 3·0) 1·3% (0·6 to 2·1) 0·9% (0·5 to 1·4)
PPV (2% incidence)¶ ·· ·· ·· 6·7% (3·5 to 11·8) 4·6% (2·5 to 7·1) 3·3% (2·5 to 3·9)
NPV§ 99·2% (98·8 to 99·6) 99·6% (99·2 to 99·9) 99·7% (99·3 to 99·9) 99·4% (99·0 to 99·8) 99·5% (99·1 to 99·9) 99·7% (99·2 to 100·0)
NPV (2% incidence)¶ ·· ·· ·· 97·9% (97·6 to 98·5) 98·2% (97·5 to 99·2) 98·8% (97·4 to 100·0)
NNS or NNT|| 29·9 (21·8 to 46·6) 37·8 (25·5 to 65·7) 83·1 (53·2 to 179·8) 75·1 (40·4 to 277·5) 123·8 (47·2 to 834·1) 168 (–440 to 1059)
Data are risk ratio (95 %CI), % (95% CI), AUC (95% CI), or NNS or NNT (95% CI). ITT=intention to treat. mITT=modified intention-to-treat. IGRA=interferon γ release assay. AUC=area under the receiver operating 
characteristic curve. PPV=positive predictive value. NPV=negative predictive value. NNS=number needed to screen. NNT=number needed to treat. *Computed over 15-month prognostic window. Performance 
of RISK11 and IGRA for incident tuberculosis over 6-month and 12-month prognostic windows is in the appendix (p 16). †RISK11 score threshold at 60% or 26%. ‡AUC is computed across all score thresholds and 
value is presented under RISK11(60). §Computed using the prevalence and incidence rates in the trial population as appropriate. ¶Computed assuming 2% annual incidence of tuberculosis in the population. 
||NNS for prevalent tuberculosis; NNT for incident tuberculosis. Performance of RISK11 and IGRA for prevalent and incident tuberculosis based on secondary endpoint (≥1 sample+) is in the appendix (p 15).
Table 2: Performance of RISK11 and IGRA for prevalent and incident tuberculosis
Total (n=2923) RISK11 positive and
3HP positive (n=375)










Female 1585 (54·2%) 213 (56·8%) 469 (61·4%) 903 (50·6%) <0·001
Male 1338 (45·8%) 162 (43·2%) 295 (38·6%) 881 (49·4%) ··
Age, years 28·5 (9·0) 28·8 (9·5) 28·4 (9·2) 28·4 (8·7) 0·541
Race or ethnicity
Asian 4 (0·1%) 0 1 (0·1%) 3 (0·2%) 0·567
Black African 1947 (66·6%) 227 (60·5%) 477 (62·4%) 1243 (69·7%) <0·001
White 4 (0·1%) 0 1 (0·1%) 3 (0·2%) 0·567
Mixed race 968 (33·1%) 148 (39·5%) 285 (37·3%) 535 (30·0%) <0·001
Body-mass index, kg/m² 24·6 (7·7) 24·1 (6·3) 24·4 (6·1) 24·9 (8·6) 0·354
Previous tuberculosis 230 (7·9%) 36 (9·6%) 75 (9·8%) 119 (6·7%) 0·003
Smoking 1478 (50·6%) 203 (54·1%) 391 (51·2%) 884 (49·6%) 0·170
Family tuberculosis history 462 (15·8%) 66 (17·6%) 110 (14·4%) 286 (16·0%) 0·675
Interferon γ release assay positive 1895 (64·8%) 250 (66·7%) 528 (69·1%) 1117 (62·6%) <0·001
Follow-up, months 15 (9·4–15·0) 15 (11·1–15·0) 15 (9·1–15·0) 13·6 (9·4–15·0) 0·056
Prevalent tuberculosis, n (probability, 95% CI) 61 (1·1%, 0·77–1·6)† 47 (4·1%, 3·1–5·4)‡ 47 (4·1%, 3·1–5·4)§ 14 (0·78%, 0·47–1·3) NA
Incident tuberculosis, n (cases per 100 person 
years, 95% CI)
24 (1·05, 0·59–1·5)§ 6 (1·9, 0·35–3·5) 14 (2·09, 0·97–3·19) 10 (0·80, 0·30–1·30) NA
Cumulative tuberculosis, n (probability, 95% CI)¶ 85 (0·022, 0·016–0·028)† 61 (0·066, 0·049–0·084)||** 61 (0·066, 0·049–0·084)** 24 (0·018, 0·011–0·026) NA
Data are n (%), mean (SD), or median (IQR), unless stated otherwise. Secondary tuberculosis endpoints by group are in the appendix (p 13). NA=not applicable. *For continuous data, p values from Wilcoxon rank sum 
test. For categorical data, p values from Fischer’s exact test. †Overall rate estimates are weighted combinations of the enrolled participants to reflect the screened population. ‡Overall incidence and cumulative 
tuberculosis excludes RISK11-positive and 3HP-positive incident cases. §Prevalent tuberculosis among RISK11 positive was assessed by combining the 3HP-negative and 3HP-positive groups. Value is repeated for 
RISK11 positive and 3HP positive, and RISK11 positive and 3HP negative. ¶Probability of observing prevalent or incident tuberculosis over 15 months. ||Probability of prevalent or incident tuberculosis not estimated for 
RISK11-positive and 3HP-positive because it would combine data from before and after 3HP treatment and is therefore potentially misleading. **Estimate for RISK11 positive includes 3HP-positive prevalent cases and 
3HP-negative prevalent and incident cases. Value is repeated for RISK11 positive and 3HP positive, and RISK11 positive and 3HP negative.
Table 1: Baseline characteristics and primary tuberculosis endpoints by group
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groups. Fisher’s exact test was used to compare binary 
readouts; p values in tables 1 and 2 were not adjusted for 
multiple comparisons. The prespecified statistical analysis 
plan is included in the appendix (p 82) and contains 
detailed description of the statistical methods.
The study was designed to have 90% power to reject the 
null hypothesis of a RISK11-positive and RISK11-negative 
cumulative risk ratio less than 2 with one-sided alpha of 
0·025. For treatment efficacy there was 80% power to 
reject the null hypothesis of efficacy less than 20%, with 
one-sided alpha of 0·05 and under the alternative design 
hypothesis that efficacy was 80%. To compute statistical 
power for these aims, a stochastic simulation of the trial 
was constructed, based on which we expected to observe 
33 tuberculosis disease endpoints among 1500 RISK11-
positive participants and seven tuberculosis disease 
endpoints among 1700 RISK11-negative partici pants 
(appendix p 6).
Role of the funding source
The trial was funded by the Bill & Melinda Gates 
Foundation (OPP1116632, OPP1137034) and the Strategic 
Health Innovation Partnerships Unit of the South 
African Medical Research Council, with funds received 
from the South African Department of Science and 
Technology. The Gates Foundation contributed to the 
study design. The regulatory sponsor was the University 
of Cape Town. Rifapentine (PRIFTIN) was donated by 
the manufacturer (Sanofi), who had no role in the design, 
implementation, analysis, or reporting of the trial. All 
authors had access to all the data reported in the study. 
The corresponding author had final responsibility for the 
decision to submit for publication.
Results
Between Sept 20, 2016, and Oct 19, 2018, 20 207 volunteers 
consented to participation; 16 248 met inclusion 
criteria at screening and 15 777 with a RISK11 result 
were potentially eligible for enrolment (figure 2). Of the 
20 207 adults assessed for eligibility, common reasons 
for exclusion included HIV infection (1246 [6·1%]) 
and comorbid conditions (1369 [6·8%]; appendix p 8). 
2923 eligible participants were enrolled after randomisation 
(1784 [61·0%] RISK11 negative and 1139 [39·0%] RISK11 
positive; table 1).
Participants were enrolled at five geographically diverse 
sites across South Africa (appendix pp 9–11). Among 
participants with a RISK11 result, 1434 (9·3%) of 15 494 
were RISK11 positive, with the proportion ranging from 
6·2% to 13·0% across the five sites. RISK11-positive 
participants were randomly asigned either to receive 
treatment (375 [32·9%] RISK11 positive and 3HP 
positive) or undergo observation without treatment 
(764 [67·1%] RISK11 positive and 3HP negative).
There were no significant differences in smoking 
history, family history of tuberculosis, or febrile illness 
between RISK11-positive and RISK11-negative partic-
ipants (table 1). A higher proportion of RISK11-positive 
(75 [9·8%] of 364) than RISK11-negative (119 [6·7%] 
of 1784) participants reported previous tuberculosis 
Figure 2: Trial profile
ITT=intention to treat. mITT=modified intention to treat. LTFU=lost to follow-up. PP=per protocol analysis. 
*585 participants did not complete the trial for reasons including: 53 (9%) pregnancies, 22 (4%) investigator 
withdrawals, 46 (8%) consent withdrawals, 26 (4%) HIV infections, 422 (72%) LTFU, and 16 (3%) deaths.
1139 RISK11 positive
2923 enrolled
3663 randomised to enrolment
15 494 with RISK11 result were
 randomised
16 248 met inclusion criteria
20 207 adults assessed for eligibility
3959 excluded
375 RISK11 positive and
 3HP positive
375 included in ITT analysis
338 included in mITT analysis
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disease (p=0·003). Compared with RISK11 negative parti-
cipants, a greater proportion of RISK11-positive parti-
cipants were female and mixed race (p<0·001; table 1).
Median duration of follow-up for incident tuberculosis 
was 13·9 months (IQR 9·0–15·0) and 1879 (66%) of 
2500 3HP-negative mITT participants attended at least 
six scheduled visits. 1416 (49%) of 2838 participants were 
followed up for 15 months and 2160 (75%) of 2838 partici-
pants were followed up for at least 9 months. 585 (21%) 
of 2838 participants did not complete the study because 
of withdrawal, death, or loss to follow-up (figure 2; 
table 1).
Among 91 participants with tuberculosis who reached 
the primary endpoint, 61 were diagnosed with prevalent 
tuberculosis at baseline (47 RISK11 positive and 
14 RISK11 negative; table 1; appendix p 13). Prevalence of 
tuberculosis in RISK11-positive and RISK11-negative 
participants was 4·1% (95% CI 3·1–5·4) and 
0·78% (0·5–1·3), respectively (figure 3). Thereafter, 
24 participants in the untreated group were diagnosed 
with incident tuberculosis disease (14 RISK11 positive 
and ten RISK11 negative; table 1; appendix p 13) with 
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Symptomatic AUC 0·97 (0·95–0·99)






Figure 3: RISK11 detection of combined prevalent and incident tuberculosis and diagnostic performance
(A) Prevalence of tuberculosis in RISK11-positive (47 cases,) and RISK11-negative (14 cases, red bar) participants at trial enrolment. Error bars depict 95% CI. 
Cumulative incidence probability of tuberculosis in RISK11-positive (14 cases, blue line) or RISK11-negative (10 cases, red line) mITT participants during follow-up. 
Shaded areas represent 95% CI. (B) Ratio of RISK11-positive versus RISK11 negative cumulative incidence probability of observing prevalent or incident tuberculosis 
disease, in the ITT population of the observation group. (C) RISK11 signature scores (each dot represents a participant) measured at screening in trial participants, 
stratified on tuberculosis diagnosis. Boxes depict IQR, midline represents the median, and whiskers indicate range among enrolled participants. (D) RISK11 signature 
scores measured at screening in prevalent tuberculosis cases with or without any tuberculosis symptoms, in incident tuberculosis cases or those who did not have a 
tuberculosis diagnosis. The enrolled population, not the screened population, is represented in (C) and (D), because a large fraction of RISK11-negative participants 
were not enrolled by design. (E) ROC curves depicting RISK11 diagnostic performance for prevalent tuberculosis in the ITT population, for prevalent tuberculosis 
among individuals with no symptoms of tuberculosis (asymptomatic) and among individuals with at least one symptom consistent with tuberculosis disease 
(symptomatic). Shaded areas represent the 95% CI. The grey and black dots indicate the minimum and optimal criteria, respectively, set out in the WHO target 
product profile for a triage test. The empty dot indicates the criteria set out in the WHO target product profile for a confirmatory diagnostic test. TRP=true positive 
rate. ITT=intention to treat. FPR=false positive rate. AUC=area under the receiver operating characteristic curve.
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In the primary analysis of biomarker performance 
for cumulative tuberculosis, cumulative probability of 
observing prevalent or incident tuberculosis disease in 
the ITT population was 0·066 (95% CI 0·049–0·084) in 
RISK11-positive participants and 0·018 (0·011–0·025) 
in RISK11-negative participants, with a risk ratio of 
3·69 (95% CI 2·25–6·05) over 15 months (figure 3).
A wide range of RISK11 scores was observed, 
irrespective of tuberculosis outcome (figure 3). Among 
enrolled participants, those who remained tuberculosis 
free (controls) had significantly lower RISK11 scores 
(24·2%, IQR 8·2–75·3) than those with prevalent 
or incident tuberculosis disease (76·7%, 36·6–94·4; 
Wilcoxon rank-sum test p<0·0001; figure 3).
In the secondary analysis of biomarker performance for 
prevalent tuberculosis, using the prespecified RISK11 test 
threshold (60%) there was 5·13-times (95% CI 3·01–10·69) 
increased risk of prevalent tuberculosis disease at baseline 
in RISK11-positive versus RISK11-negative participants, 
with sensitivity of 35% (95% CI 24–52) and specificity of 
91% (95% CI 91–91; table 2). The receiver operating 
characteristic (ROC) analysis (figure 3) showed that a 
RISK11 threshold of 26% provided sensitivity of 72% 
(95% CI 54–90) and specificity of 75% (95% CI 73–76; 
table 2); with area under the diagnostic ROC curve (AUC) 
of 0·77 (95% CI 0·68–0·86). These performance estimates 
did not meet the minimum criteria for a tuberculosis 
triage test (table 2). 50 (83·6%) of 61 participants with 
prevalent tuberculosis had no symptoms compatible with 
tuberculosis disease, and the remaining 11 participants 
with at least one symptom consistent with tuberculosis 
had RISK11 scores of more than 80% (median 96%; 
figure 3; appendix p 14). Discrimi nation between 
symptomatic prevalent tuberculosis and symptomatic 
controls was high (AUC 0·97, 95% CI 0·95–0·99; figure 3) 
and, with a highly specific threshold, performance 
exceeded the optimal TPP for a tuberculosis triage test 
in this population. By contrast, RISK11 discriminated 
Figure 4: Prognostic performance of RISK11 and treatment efficacy of 3HP
(A) ROC curve depicting RISK11 prognostic performance for incident tuberculosis through 15 months of follow-up. The shaded area represents 95% CI. The grey and black 
dots depict the minimum and optimal criteria, respectively, set out in the WHO target product profile for an incipient tuberculosis test. (B) RISK11 performance (area under 
the ROC curve) for endpoints within a 6-month sliding window from month 0 through 15. The shaded area represents 95% CI. (C) ROC curves depicting RISK11 prognostic 
performance for incident tuberculosis through expanding follow-up periods. The grey and black dots depict the minimum and optimal criteria, respectively, set out in the 
WHO target product profile for an incipient tuberculosis test. (D) Cumulative incidence of tuberculosis in RISK11-positive participants who were randomly assigned to 3HP 
(six cases, red line) and RISK11-positive participants who were randomly assigned to observation (14 cases, blue line) during follow-up. The shaded areas represent 
95% CI. (E) Cumulative incidence of tuberculosis in participants who met criteria for treatment adherence per protocol, stratified into RISK11-positive participants who 
were randomly assigned to 3HP (four cases, red line) and RISK11-positive participants who were randomly assigned to observation (14 cases, blue line) during follow-up. 
(F) TE estimated through follow-up in participants who met criteria for treatment adherence per protocol. The shaded areas represent 95% CI. TRP=true positive rate. 
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 0–15 AUC 0·63
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TE 22·0% (–137 to 74·4)
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between asymptomatic controls and asymptomatic 
prevalent tuberculosis cases with an AUC of 0·75 (95% CI 
0·66–0·84; figure 3).
In the secondary analysis of biomarker performance 
for incident tuberculosis, annualised incidence was 
2·1 versus 0·8 per 100 person-years among the RISK11-
positive versus RISK11-negative participants, respectively, 
which was equivalent to a 0·026 (95% CI 0·01–0·04) 
versus 0·010 (0·004–0·02) cumulative incident probability 
of developing tuberculosis disease over 15 months, 
respectively (figure 3). No incident tuberculosis cases were 
detected in RISK11-negative participants until 8·7 months 
(figure 3). Tuberculosis incidence through 15 months 
among RISK11-positive participants was 2·61 (95% CI 
1·15–5·94) times higher than RISK11-negative participants 
(table 2); and the RISK11 signature discriminated between 
incident tuberculosis cases and controls with AUC of 
0·63 (95% CI 0·47–0·80; figure 4). Over this period, at the 
predefined 60% threshold, RISK11 showed very low 
sensitivity of 25% (95% CI 12–46) with specificity of 
91% (95% CI 91–91). At an exploratory RISK11 threshold 
of 26%, which provided 75% specificity, sensitivity was 
47% (95% CI 26–74). By comparison, the prognostic 
sensitivity of IFNγ release assays over 15 months 
was 83% (62–100), but more than 60% of the population 
was IFNγ release assay positive (specificity 37%, 95% CI 
35–40; table 2).
RISK11 prognostic performance was highly dependent 
on time to disease. Instantaneous RISK11 performance, 
estimated from 6-month sliding windows, showed 
prognostic discrimination was high (AUC >0·80) for 
approximately 9 months, before waning towards 0·58 
between months 9 and 15 (figure 4; appendix p 16). 
Prognostic performance of RISK11 for incident 
tuberculosis within 6 months (AUC 0·95, 95% CI 
0·92–1·0) exceeded the optimal TPP for an incipient 
tuberculosis test (appendix p 16), and for tuberculosis 
disease within 12 months (0·80, 0·65–0·94; figure 4) 
approached the minimum TPP (appendix p 16), but over a 
15-month period did not meet minimum criteria for a 
prognostic tuberculosis test (table 2).
In the primary analysis of treatment efficacy among 
RISK11-positive participants, tuberculosis incidence in the 
3HP-positive and 3HP-negative groups was 1·94 cases per 
100 person years and 2·09 cases per 100 person years, 
respectively (figure 4; table 1), with estimated treatment 
efficacy of 7·0% (95% CI –145 to 64·7) over 15 months. In 
the subgroup of 286 adherent participants who completed 
at least 11 doses within 16 weeks, efficacy was 22% 
(–138 to 74; figure 4) over 15 months. Notably, among 
adherent participants, there were no tuberculosis cases 
through 9 months (figure 4).
Adverse events related to 3HP were mostly of mild to 
moderate severity (appendix p 12). 67 serious adverse 
events, including 29 due to trauma, occurred in 
65 participants. Serious adverse events occurred in 
20 (5·3%) of 375 RISK11-positive participants who 
received 3HP (eight serious adverse events due to 
trauma), compared with 12 (1·6%) of 764 in RISK11-
positive and 3HP-negative participants (Fisher’s exact 
p<0·001). Among RISK11-negative participants, 33 (1·9%) 
of 1784 experienced serious adverse events. All but two 
serious adverse events were deemed unrelated to 3HP. 
Serious adverse events related to 3HP included one 
hospitalisation for seizures (unintentional isoniazid 
overdose) and one death of unknown cause (possibly 
temporally related). One death of unknown cause also 
occurred in an untreated RISK11-negative participant. 
There were 16 deaths in total, including five RISK11-
positive participants receiving 3HP (three deaths due to 
trauma), three untreated RISK11-positive participants, 
and eight RISK11-negative participants.
3HP was halted in 28 (7·5%) of 375 participants, due to 
an adverse event of special interest (influenza-like illness 
or other possible hypersensitivity reaction) in 17 (4·5%), 
hepatotoxicity in one (0·3%), gastrointestinal symptoms 
in three (0·8%), and seizures in three (0·8%) participants.
RISK11 diagnostic and prognostic performance and 
treatment efficacy of 3HP based on the secondary endpoint 
definition (at least one sputum sample; appendix p 14) are 
described in the appendix (p 15).
Five (8·2%) of the 61 participants witih prevalent 
tuberculosis were resistant to isoniazid or rifampicin, or 
both. Two (6·7%) of the 30 participants with incident 
tuberculosis, both in the untreated group, were resistant 
to isoniazid and rifampicin. No participants were 
observed to have drug-resistant incident tuberculosis in 
the 3HP-positive group.
Discussion
Our goal was to evaluate a biomarker-targeted, community-
based strategy to detect missing tuberculosis cases among 
people who do not seek health care, whose disease might 
not be detected by symptom-focused screening algorithms, 
and to prevent disease among those at highest risk of 
progression to tuberculosis. The RISK11 assay was an 
effective screening test for active disease in symptomatic 
participants, in whom performance exceeded the require-
ments for a triage test, but less so in asymptomatic 
participants. The RISK11 signature was able to predict risk 
for tuberculosis disease progression, in a trial population 
with tuberculosis incidence exceeding one case per 
100 person-years, but optimal prognostic performance 
was limited to a 6-month horizon. While risk-targeted 
3HP did not prevent tuberculosis disease over 15 months, 
there was some evidence of transient efficacy through 
9 months among fully adherent participants.
Community-based recruitment of ambulant volunteers 
was not focused on individuals with known risk factors 
for tuberculosis, such as household contact. Individuals 
with recent previous history of tuberculosis (>3 years 
before screening) and HIV infection were excluded. 
Nevertheless, more than 1% of study volunteers had 
previously undiagnosed, microbiologically confirmed 
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tuberculosis at enrolment, based on spontaneous 
expectorated rather than induced sputum samples. More 
than 80% of these baseline tuberculosis cases did not 
have any symptom compatible with tuberculosis disease 
and would not have been detected by a tuberculosis 
screening strategy that requires symptoms as the entry 
point to investigation. This finding is consistent with 
46–79% prevalence (median 50%) of subclinical tubercu-
losis reported in prevalence surveys.12–14 It is not known 
whether subclinical tuberculosis would have progressed 
to symptomatic disease, spontaneously halted, or even 
reversed if left untreated,15,16 nor whether subclinical 
disease directly contributes to M tuberculosis trans-
mission.17 Further research is needed to determine the 
importance of detection, treatment, and prevention of 
subclinical disease for global tuberculosis control.
Although very few prevalent tuberculosis cases were 
symptomatic, RISK11 performance for discrimination of 
symptomatic prevalent tuberculosis cases from sympto-
matic controls exceeded the optimal TPP criteria for a 
triage test, while not meeting the stringent criteria for 
a confirmatory diagnostic test.5 A 2020 prospective 
observational study among symptomatic individuals who 
self-presented to a tuberculosis clinic assessed diagnostic 
accuracy of 27 transcriptomic signatures for discrimi-
nation between prevalent tuberculosis cases and 
controls.18 The 16-gene Zak signature, from which RISK11 
was derived, did not meet the minimum WHO criteria 
for a triage test, but four of the 27 signatures met these 
criteria, suggesting that another signature might perform 
as well as or better than RISK11. RISK11 discrimination 
of asymptomatic prevalent tuberculosis cases from 
asymptomatic controls was modest and did not meet the 
minimal criteria for a triage test. These findings suggest 
that host blood biomarker development must consider 
that subclinical tuberculosis might be characterised by 
more heterogenous or less pronounced peripheral blood 
inflammatory responses than symptomatic tuberculosis, 
or both, which affects RNA signature performance. This 
finding is consistent with lower inflammatory profiles, 
observed by blood transcriptomic and proteomic 
analyses, during the subclinical phases of tuberculosis 
progression compared with subsequent symptomatic, 
active disease.19,20 The modest performance characteristics 
for asymptomatic prevalent tuberculosis would limit 
applicability of RISK11 for biomarker-targeted, mass 
community screening in the South African setting, 
where the majority of baseline tuberculosis cases were 
subclinical. A host blood biomarker with good sensitivity 
and specificity for symptomatic tuberculosis might be 
most useful in countries with low to medium tuberculosis 
burden, where individuals with compatible symptoms 
might not otherwise be investigated for tuberculosis. 
Future diagnostic studies in symptomatic patients 
seeking health care should also include patients with 
extra pulmonary and culture-negative tuberculosis, 
particularly in HIV-infected cohorts, and the full 
spectrum of differential diagnoses that commonly mimic 
tuberculosis.
Prognostic performance of RISK11 for risk of 
progression to incident tuberculosis was poor through 
15 months and did not meet the minimum TPP criteria 
for an incipient tuberculosis test through this prognostic 
horizon.4 However, good prognostic performance was 
observed for incident tuberculosis within 12 months of 
testing and performance exceeded the optimal TPP 
criteria for tuberculosis occurring within 6 months of 
testing. The positive predictive value for incident disease 
(1·9 vs 0·9 for RISK11 compared with IFNγ release 
assay, respectively) was computed from the observed 
tuberculosis incidence rate, which was lower than that 
typically used in estimations (2%).3,6 It is not possible to 
determine whether the late incident tuberculosis cases 
occurring among RISK11-negative participants were 
due to reactivation or new M tuberculosis infection. We 
infer that a prognostic test with optimal short-term 
performance might be useful in identifying people who 
would benefit from an efficacious intervention in a low-
incidence setting, in which the timing of M tuberculosis 
exposure is often known and subsequent exposure is 
unlikely.
The 3HP regimen was previously shown to be as 
effective as 9 months of isoniazid in preventing 
tuberculosis among individuals with known exposure or 
positive TST.21 Ethical equipoise of the intervention and 
control groups in this trial was based on the fact that 
RISK11 had been validated in selected case-control 
studies, which can overestimate biomarker performance, 
and thus risk for tuberculosis among RISK11-positive 
individuals needed to be tested prospectively in the field. 
Furthermore, although TPT is given commonly to IFNγ 
release assay-positive and tuberculin skin test-positive 
individuals, and individuals with known household 
exposure to a tuberculosis patient, the vast majority do 
not progress to tuberculosis disease if left untreated. The 
risk–benefit balance of 3HP preventive therapy for 
RISK11-positive individuals was unknown. However, we 
found no evidence that 3HP treatment reduced the rate 
of incident tuberculosis over 15 months in RISK11-
positive individuals, who might be further advanced 
along the spectrum of tuberculosis pathogenesis.19 
Interpretation of the results is limited by the wide CIs. It 
is also notable that no tuberculosis cases were observed 
in fully adherent participants through 9 months. This 
finding is consistent with the possibility that 3HP was 
sufficient to temporarily halt, but insufficient to sterilise, 
incipient tuberculosis, resulting in reactivation. A 
RISK11-targeted preventive therapy strategy for high 
tuberculosis transmission settings like South Africa 
might require a more potent therapeutic regimen than 
3HP. 3HP might have been sufficient to sterilise 
incipient tuberculosis disease, but not to protect against 
tuberculosis disease resulting from reinfection after 
completion of the treatment course. Although it is 
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not possible to distinguish between reactivation and 
reinfection tuberculosis cases in this study, we suggest 
that the limited time available for reinfection and 
subsequent progression to disease after completing 3HP 
makes the latter possibility less likely.
The study was subject to a number of limitations. The 
hybrid design required an open-label treatment group,2 
with no placebo for RISK11-positive participants, so that 
risk for tuberculosis could also be evaluated in the control 
group while concealing RISK11 status from participants, 
site staff, and tuberculosis endpoint laboratory staff for 
analysis of biomarker performance. Tuberculosis case 
accrual during the latter stages of follow-up suggested no 
evidence of ascertainment bias during treatment. Extensive 
study simulations were done to inform the size of each 
group for the coprimary analyses. However, due to 
lower than expected prevalence of RISK11-positive status 
in the screened population (9·3% vs 15%), enrolment of 
1139 RISK11-positive individuals required 2 years, 
compared with planned enrolment of 1500 RISK11-positive 
individuals over 1 year. As a result, fewer than expected 
incident tuberculosis outcomes were observed (24 vs 
40 primary endpoints), which might have reduced power 
for both treatment efficacy and RISK11 performance 
analyses. Not all participants in the treatment group 
completed 3HP per protocol, because study drug was 
discontinued for suspected hyper sensitivity reactions or 
influenza-like illnesses. However, the discontinuation 
rate (7·5%) was comparable to other trials of 3HP, in 
which study drug was discontinued in 17·9% of parti-
cipants overall and in 4·9% due to an adverse event.21 The 
loss to follow-up rate in this trial (14·4%) was higher than 
expected and might reflect the challenges of retaining the 
study participants, in the absence of traditional tuberculosis 
risk factors for which surveillance is routine. However, loss 
to follow-up occurred predominantly after the treatment 
period and did not seem to have been biased by treatment 
factors. We note that median duration of participation was 
13·9 months and thus loss to follow-up did not have major 
unforeseen effect on statistical power. Strengths of the 
study include enrolment in geographically distinct sites 
across South Africa that were representative of populations 
with different rates of IFNγ release assay positivity and 
tuberculosis disease, which were congruent with local 
rates of RISK11 positivity, although the sample size was not 
sufficient for analysis of signature performance or 3HP 
efficacy at site level. The findings broadly reflect the South 
African tuberculosis epidemic, but might not be directly 
applicable to countries with much lower tuberculosis 
incidence.
It is not yet known whether other parsimonious 
tuberculosis signatures, developed and validated like 
RISK11 in carefully curated case-control studies, will 
exhibit similar performance characteristics when pros-
pectively tested in the field, where undiagnosed 
subclinical tuberculosis might pose a challenge to 
diagnostic perfor mance. Head-to-head analyses of 
several transcriptomic tuberculosis signatures with pro-
mising diagnostic perfor mance are currently underway 
on CORTIS samples and novel near-patient testing 
platforms are in develop ment, which might bring cost-
effective, community-based tuberculosis biomarker 
screening closer to implementation in the field. 
However, although we have shown that a strategy of 
biomarker-guided tuberculosis preventive therapy is 
feasible, the optimal preventive therapy regimen for use 
in such a strategy remains elusive.
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